Replimune Group's stock fell sharply by 38.01% following FDA briefing documents that deemed its skin cancer drug trial data "not interpretable," signaling a major regulatory setback. Other companies like Travelzoo and Amkor Technology also saw significant stock declines due to earnings misses and sector volatility. These events highlight how regulatory challenges and broader market conditions can heavily impact stock prices. Investors should watch upcoming earnings and regulatory updates closely.
Seagate Technology reported strong Q4 2026 results, beating earnings per share estimates with $5.71 and revenue of $3.63 billion, driven by high demand for data storage from the AI sector. The company showed solid financial health with a low debt-to-...
Polaris Inc. reported a strong quarterly performance with earnings per share of $1.97, beating estimates by over 155%, and revenues of $2.02 billion, up 9.2% year-over-year. The growth was driven by sales recovery in the utility off-road vehicle segm...
Seagate Technology is set to report its Q2 2026 earnings with analysts expecting an EPS of $5.10 and revenue around $3.5 billion, reflecting strong demand for data storage driven by AI growth. The company's optimistic guidance aligns with these estim...
Teladoc Health, a leader in virtual healthcare services, has seen its average analyst price target rise from $8.35 to $11.00, reflecting increased confidence in its market position. The stock recently jumped 6.1% with high trading volume, driven by r...
Procter & Gamble, a leading consumer goods company and Dividend King, is seeing a decline in analyst price targets from $162.52 to $152 over the past year, though Deutsche Bank remains optimistic with a $177 target. Despite a strong history of beatin...
